Antibiotics Developer Plans Ch. 11 Sale To Escape $213M Debt
Antibiotics developer Melinta Therapeutics Inc. has filed for Chapter 11 in Delaware bankruptcy court, saying it hopes to close a going-concern sale by the spring to escape more than $213 million...To view the full article, register now.
Already a subscriber? Click here to view full article